ERDERA Launches the 2025 Joint Transnational Call for Proposals on Rare Disease Therapies 

ERDERA Launches the 2025 Joint Transnational Call for Proposals on Rare Disease Therapies

The European Rare Diseases Research Alliance (ERDERA) is delighted to announce the official launch of its 2025 Joint Transnational Call (JTC) for Proposals as of today, 10 December 2024. This eagerly anticipated call invites research teams across Europe and internationally to collaborate on cutting-edge projects aimed at “Pre-clinical therapy studies for rare diseases using small molecules and biologicals – development and validation.” 

See all the details of the official call here.  

Application Timeline 

The JTC 2025 will follow a two-stage submission process: 

  • 13 February 2025: Pre-proposal submission deadline. 
  • 9 July 2025: Full proposals submission deadline. Funding decisions are expected by December 2025. 

Interested applicants can join an informational webinar on 17 December 2024, providing valuable guidance on preparing submissions. 

For more information, contact the Joint Call Secretariat at SelteneErkrankungen@dlr.de or reach out to the relevant national contact point. 

Stay informed with the latest updates from ERDERA by subscribing to our newsletter and following us on social media. 

News & Updates

You might also be interested in

European Parliament

European Parliament draft report urges a binding EU rare disease action framework

A legislative own initiative file in the Parliament’s new public health committee sets out what an EU “rare disease action framework” could look like — and why it could change how Europe measures progress for patients.
Woman helping out a person with a disease

Women’s Day highlights widening gender inequalities in rare diseases

Drawing on Europe-wide patient and carer surveys, ERDERA highlights how gender can shape diagnostic delays, care burden and the evidence base for rare-disease research.
European Parliament Photograph

New European Parliament study maps options for an EU rare disease action plan

European Parliament research service assessment, published in February 2026, identifies 31 measures that could form an EU rare disease action plan, highlighting European Reference Networks and cross-border collaboration including ERDERA as drivers of EU added value.
Publicaciones (1)

EU rare disease action plan- European Added Value Assessment

This study investigates possible measures that could be taken at EU level to address these challenges. It finds significant European added value in harmonising coordination and access across the 27 Member States, mainly in terms of improved diagnostic tools and availability of medical treatment, better health outcomes, particularly lower infant mortality, and improved well-being of family members and caregivers.

ERDERA's

search form